Association of plasma BDNF and MMP-9 levels with mild cognitive impairment: a matched case-control study DOI Creative Commons
Tingyu Zhang, Hang Si, Jiali Liao

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 28, 2024

The prevalence of Alzheimer's disease (AD) is on the rise globally, and everyone who develops AD eventually experiences mild cognitive impairment (MCI) first. Timely intervention at an early stage may mitigate progression. Recent studies indicate that BDNF MMP-9 play a significant role in pathogenesis AD. Therefore, this study aims to ascertain whether there are differences plasma levels between individuals with due those normal cognition, analyze factors influencing impairment.This case-control included 102 controls, matched by age sex. Participants completed series questionnaires, neuropsychological assessments, clinical examinations. Plasma concentrations participants were quantified using ELISA. Subsequently, MCI analyzed univariate multivariate logistic regression. levels, MOCA total scores, scores various domains (including visuospatial executive abilities, abstract thinking, attention, language, naming, delayed memory) control groups showed statistically (p < 0.05). Logistic regression analysis revealed years formal education significantly negatively associated MCI. This indicates protective function.

Language: Английский

Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays DOI Creative Commons
Daniel Figdore, Michael Griswold, Joshua A. Bornhorst

et al.

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(9), P. 6506 - 6516

Published: July 19, 2024

Abstract INTRODUCTION We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p‐tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status implementation in practice. METHODS Clinical performance p‐tau217 against positron emission tomography was evaluated participants with mild cognitive impairment or dementia ( n = 427). RESULTS Using a one‐cutpoint approach (negative/positive), neither assay achieved ≥ 90% both sensitivity specificity. A two‐cutpoint yielding 92% 96% specificity provided the desired balance false positives negatives, while categorizing 20% 39% results indeterminate Lumipulse ALZpath assays, respectively. DISCUSSION This study provides systematic framework selection assay‐specific use determination status. Our findings suggest that may have advantages optimizing diagnostic accuracy minimizing potential harm from positive results. Highlights Phosphorylated detection pathology were established. exhibited best laboratory use. differed percentage categorized intermediate.

Language: Английский

Citations

16
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions DOI Creative Commons
Angeliki Zarkali, George E. Thomas, Henrik Zetterberg

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 5, 2024

Abstract A major challenge in Parkinson’s disease is the variability symptoms and rates of progression, underpinned by heterogeneity pathological processes. Biomarkers are urgently needed for accurate diagnosis, patient stratification, monitoring progression precise treatment. These were previously lacking, but recently, novel imaging fluid biomarkers have been developed. Here, we consider new approaches showing sensitivity to brain tissue composition, examine specificity processes, including seed amplification assays extracellular vesicles. We reflect on these context biological staging systems, emerging techniques currently development.

Language: Английский

Citations

14
A critical appraisal of blood-based biomarkers for Alzheimer’s disease DOI
Simone Lista, Mark Mapstone, Filippo Caraci

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 96, P. 102290 - 102290

Published: April 1, 2024

Language: Английский

Citations

12
Alzheimer’s disease biomarkers and their current use in clinical research and practice DOI
T. Hunter, Luís E. Santos, Fernanda Tovar‐Moll

et al.

Molecular Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 4, 2024

Language: Английский

Citations

12
Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer’s Disease in Blood DOI Creative Commons

Jianman Wang,

Xing Lü, Yao He

et al.

Biosensors, Journal Year: 2025, Volume and Issue: 15(2), P. 85 - 85

Published: Feb. 4, 2025

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder and significant cause of dementia in elderly individuals, with growing prevalence our aging population. Extracellular amyloid-β peptides (Aβ), intracellular tau proteins, their phosphorylated forms have gained prominence as critical biomarkers for early precise diagnosis AD, correlating progression response to therapy. The high costs invasiveness conventional diagnostic methods, such positron emission tomography (PET) magnetic resonance imaging (MRI), limit suitability large-scale or routine screening. However, electrochemical (EC) analysis methods made progress detection due sensitivity, excellent specificity, portability, cost-effectiveness. This article reviews the EC biosensing technologies, focusing on protein blood (a low-invasive, accessible medium). then discusses various sensing platforms, including fabrication processes, (LOD), clinical potential show role these sensors transformers changing face AD diagnostics.

Language: Английский

Citations

1
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study DOI Creative Commons
Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 22, 2024

BACKGROUND: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimers disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised clinical use. The Association Global Biomarker Standardisation Consortium plasma phospho-tau Round Robin study engaged assay developers in blinded case-control p-tau, aiming to learn which assays provide the largest fold-changes AD compared non-AD, have strongest relationship between and cerebrospinal fluid (CSF), show most consistent relationships methods (commutability) measuring both patient samples candidate reference materials (CRM). METHODS: Thirty-three different assays, built eight platforms, were used quantify paired CSF from 40 participants. status was categorised as pathology (n=25) non-AD (n=15) by Aβ42/Aβ40 (US-FDA; CE-IVDR) p-tau181 (CE-IVDR) methods. commutability of four CRM, at three concentrations, assessed across assays. FINDINGS: Plasma p-tau217 consistently demonstrated higher groups, other epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, Lilly MSD provided highest median fold-changes. In CSF, also performed best, exhibited substantially larger than their counterparts, despite similar diagnostic performance. P-tau217 showed correlations (rho=0.81 0.97). levels weakly-to-moderately correlated with non-significant within group alone. evaluated CRM not commutable INTERPRETATION: measures had discriminative accuracies detecting pathology, better agreement variants. markers measured immunoassays, correlated, questioning interchangeability continuous relationship. Further work warranted understand pathophysiology underlying this dissociation, develop suitable facilitating cross-assay standardisation. FUNDING: (#ADSF-24-1284328-C)

Language: Английский

Citations

6
Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples DOI Creative Commons
Anna Mammel, Ging‐Yuek Robin Hsiung,

Ali Mousavi

et al.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 1, 2025

Language: Английский

Citations

0
Elevated plasma Tau-PT217 linked to decreased hippocampal functional connectivity in patients with knee osteoarthritis DOI
Ya Wen,

Mattia Cannistra,

Valeria Saccà

et al.

Brain Research, Journal Year: 2025, Volume and Issue: unknown, P. 149478 - 149478

Published: Jan. 1, 2025

Language: Английский

Citations

0
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study DOI Creative Commons
Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in disease (AD) versus non-AD and show commutability measuring patient samples candidate certified reference materials (CRMs). Thirty-three different p-tau measured paired plasma cerebrospinal fluid (CSF) from 40 participants (25 with "AD pathology" 15 "non-AD by CSF amyloid beta [Aβ]42/Aβ40 p-tau181 criteria). Four CRMs were assessed. Plasma p-tau217 demonstrated higher between AD than other epitopes. Fujirebio LUMIPULSE G, UGOT IPMS, Lilly MSD provided highest fold-changes. showed strongest correlations (rho = 0.81-0.97). not commutable across assays. larger better accuracy for detecting pathology symptomatic individuals, greater cross-platform agreement variants. Further work is needed develop suitable facilitating cross-assay standardization. Paired twenty-five patients blind. compared, tau-181 (p-tau181), 205, 212, 217 231. consistently had fold-change was best correlated Plasma-CSF weak moderate. There lack of four materials.

Language: Английский

Citations

0
The Urgent and Global Need for Democratized Blood-Based Biomarker Diagnostics in Alzheimer’s Disease DOI Creative Commons
Steven D. Quinn

Published: March 1, 2025

Language: Английский

Citations

0